# EDGAR Filing Document

**Accession Number:** 0001454789
**File Stem:** 0001104659-25-102037
**Filing Date:** 2025-10
**Character Count:** 26033
**Document Hash:** d1cbd8c4dddb4c76c34a504a3903927b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-102037.hdr.sgml**: 20251024

**ACCESSION NUMBER**: 0001104659-25-102037

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20251024

**DATE AS OF CHANGE**: 20251024

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Astria Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001454789
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88910
- **FILM NUMBER:** 251415049

**BUSINESS ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 617-349-1971

**MAIL ADDRESS:**
- **STREET 1:** 22 BOSTON WHARF ROAD
- **STREET 2:** 10TH FLOOR
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATABASIS PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090127
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Magnetar Financial LLC
- **CENTRAL INDEX KEY:** 0001352851

**ORGANIZATION NAME:**
- **EIN:** 043818748
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**BUSINESS ADDRESS:**
- **STREET 1:** 1603 ORRINGTON AVE.
- **STREET 2:** 13TH FLOOR
- **CITY:** EVANSTON
- **STATE:** IL
- **ZIP:** 60201
- **BUSINESS PHONE:** (847)905-4400

**MAIL ADDRESS:**
- **STREET 1:** 1603 ORRINGTON AVE.
- **STREET 2:** 13TH FLOOR
- **CITY:** EVANSTON
- **STATE:** IL
- **ZIP:** 60201

## Exhibit 99.1

**Exhibit 99.1**

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13D with respect to the Shares of Astria Therapeutics Inc. dated as of October 24, 2025 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the previsions of Rule13d-1(k) under the Securities Exchange Act of 1934, as amended.

Date: October 24, 2025 magnetar financial llc

---

| | |
|:---|:---|
| By: Magnetar Capital Partners LP, its Sole Member | By: Magnetar Capital Partners LP, its Sole Member |
| By: | /s/ Hayley Stein |
| Name: | Hayley Stein |
| Title: | Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC, GP of Magnetar Capital Partners LP, its Sole Member |

---

Date: October 24, 2025 magnetar capital partners LP

---

| | |
|:---|:---|
| By: Supernova Management LLC, its General Partner | By: Supernova Management LLC, its General Partner |
| By: | /s/ Hayley Stein |
| Name: | Hayley Stein |
| Title: | Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC, its General Partner |

---

Date: October 24, 2025 supernova management llc

---

| | |
|:---|:---|
| By: | /s/ Hayley Stein |
| Name: | Hayley Stein |
| Title: | Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC |

---

Date: October 24, 2025 DAVID J. SNYDERMAN

---

| | |
|:---|:---|
| By: | /s/ Hayley Stein |
| Name: | Hayley Stein |
| Title: | Attorney-in-fact for David J. Snyderman |

---

## Exhibit 99.2

**EXHIBIT 99.2**

LIMITED POWER OF ATTORNEY

Know all by these present, that I, <u>David J. Snyderman</u>, hereby make, constitute and appoint each of <u>Michael Turro</u>, <u>Karl Wachter</u> and <u>Hayley Stein</u>, or any of them acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as <u>Manager</u> or in other capacities of <u>Supernova Management LLC</u>, a <u>Delaware limited liability company</u>, and each of its affiliates or entities advised or controlled by me or <u>Supernova Management LLC</u>, all documents, certificates, instruments, statements, filings and agreements ("documents") to be filed with or delivered to the United States Securities and Exchange Commission (the "SEC") pursuant to the Securities and Exchange Act of 1934, as amended (the "Act"), and the rules and regulations promulgated thereunder, including, without limitation, all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act, including, without limitation: (a) any acquisition statements on Schedule 13D or Schedule 13G and any amendments thereto, (b) any joint filing agreements pursuant to Rule 13d-1(k) under the Act, and (c) any initial statements of, or statements of changes in, beneficial ownership of securities on Form 3, Form 4 or Form 5.

All past acts of the attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

This Power of Attorney shall remain in full force and effect until the earlier of it being (a) revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact or (b) superseded by a new power of attorney regarding the purposes outlined herein as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 22 day of December, 2022.

---

| |
|:---|
| /s/ David J. Snyderman |
| David J. Snyderman |

---

## Exhibit 99.3

**Exhibit 99.3**

**SCHEDULE A**

**Funds**

---

| | | |
|:---|:---|:---|
| Date | Number of Shares Bought | Price Per Share($) <sup>(1)(2)</sup> |
| 8/26/2025 | 22 | 6.49523<sup>(3)</sup> |
| 8/27/2025 | 130 | 6.53927<sup>(4)</sup> |
| 8/28/2025 | 101 | 6.57021<sup>(5)</sup> |
| 8/29/2025 | 1306 | 6.21948<sup>(6)</sup> |
| 9/9/2025 | 4 | 7.25880<sup>(7)</sup> |
| 9/10/2025 | 20 | 7.64994<sup>(8)</sup> |
| 9/11/2025 | 28 | 7.65025<sup>(9)</sup> |
| 9/12/2025 | 23 | 7.88087<sup>(10)</sup> |
| 9/15/2025 | 94 | 7.30670<sup>(11)</sup> |
| 9/19/2025 | 1091 | 7.01918<sup>(12)</sup> |
| 9/25/2025 | 153 | 7.01690<sup>(13)</sup> |
| 10/14/2025 | 1095236 | 11.76862<sup>(14)</sup> |
| 10/15/2025 | 1263727 | 11.92812<sup>(15)</sup> |
| 10/16/2025 | 443171 | 12.05505<sup>(16)</sup> |
| 10/17/2025 | 33987 | 11.96878<sup>(17)</sup> |
| 10/20/2025 | 372857 | 12.09203<sup>(18)</sup> |
| 10/21/2025 | 38145 | 12.09262<sup>(19)</sup> |
| 10/22/2025 | 65123 | 12.22689<sup>(20)</sup> |

---

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $6.49523 per share, at prices ranging from $6.47 to $6.53 per share

(4) Reflects a weighted average purchase price of $6.53927 per share, at prices ranging from $6.5 to $6.71 per share.

(5) Reflects a weighted average purchase price of $6.57021 per share, at prices ranging from $6.5155 to $6.85 per share.

(6) Reflects a weighted average purchase price of $6.21948 per share, at prices ranging from $6.125 to $6.40 per share.

(7) Reflects a weighted average purchase price of $7.25880 per share, at prices ranging from $7.21 to $7.31 per share.

(8) Reflects a weighted average purchase price of $7.64994 per share, at prices ranging from $7.5966 to $7.7585 per share.

(9) Reflects a weighted average purchase price of $7.65025 per share, at prices ranging from $7.41 to $7.73 per share.

(10) Reflects a weighted average purchase price of $7.88087 per share, at prices ranging from $7.79 to $7.94 per share.

(11) Reflects a weighted average purchase price of $7.30670 per share, at prices ranging from $7.23 to $7.42 per share.

(12) Reflects a weighted average purchase price of $7.01918 per share, at prices ranging from $6.88 to $7.07 per share.

(13) Reflects a weighted average purchase price of $7.01690 per share, at prices ranging from $6.94 to $7.14 per share.

(14) Reflects a weighted average purchase price of $11.76862 per share, at prices ranging from $11.595 to $11.97 per share.

(15) Reflects a weighted average purchase price of $11.92812 per share, at prices ranging from $11.71 to $12.02 per share.

(16) Reflects a weighted average purchase price of $12.05505 per share, at prices ranging from $11.97 to $12.11 per share.

(17) Reflects a weighted average purchase price of $11.96878 per share, at prices ranging from $11.96 to $11.97 per share.

(18) Reflects a weighted average purchase price of $12.09203 per share, at prices ranging from $11.97 to $12.15 per share.

(19) Reflects a weighted average purchase price of $12.09262 per share, at prices ranging from $12.07 to $12.17 per share.

(20) Reflects a weighted average purchase price of $12.22689 per share, at prices ranging from $12.16 to $12.27 per share.

---

| | | |
|:---|:---|:---|
| Date | Number of Shares Sold | Price Per Share($) <sup>(1)(2)</sup> |
| 8/26/2025 | 22 | 6.47038<sup>(3)</sup> |
| 8/27/2025 | 19 | 6.66368<sup>(4)</sup> |
| 8/28/2025 | 17 | 6.74011<sup>(5)</sup> |
| 8/29/2025 | 16 | 6.34951<sup>(6)</sup> |
| 9/4/2025 | 1 | 6.66 |
| 9/8/2025 | 286 | 7.47937<sup>(7)</sup> |
| 9/9/2025 | 1027 | 7.59199<sup>(8)</sup> |
| 9/10/2025 | 20 | 7.64881<sup>(9)</sup> |
| 9/11/2025 | 113 | 7.76442<sup>(10)</sup> |

---

(1) Excludes commissions and other execution-related costs.

(2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

(3) Reflects a weighted average purchase price of $6.47038 per share, at prices ranging from $6.4203 to $6.505 per share.

(4) Reflects a weighted average purchase price of $6.66368 per share, at prices ranging from $6.58 to $6.71 per share.

(5) Reflects a weighted average purchase price of $6.74011 per share, at prices ranging from $6.71 to $6.8164 per share.

(6) Reflects a weighted average purchase price of $6.34951 per share, at prices ranging from $6.33 to $6.3607 per share.

(7) Reflects a weighted average purchase price of $7.47937 per share, at prices ranging from $7.24 to $7.5195 per share.

(8) Reflects a weighted average purchase price of $7.59199 per share, at prices ranging from $7.17 to $7.68 per share.

(9) Reflects a weighted average purchase price of $7.64881 per share, at prices ranging from $7.613 to $7.6983 per share.

(10) Reflects a weighted average purchase price of $7.76442 per share, at prices ranging from $7.59 to $7.84 per share.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**Astria Therapeutics, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**04635X102**

*(CUSIP Number)*

**David J. Snyderman**<br>1603 Orrington Avenue<br>13th Floor<br>Evanston IL 60201<br>847-905-4400

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **04635X102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Magnetar Financial LLC** | Name of reporting person<br>**Magnetar Financial LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3312202.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3312202.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.87%** | Percent of class represented by amount in Row (11)<br>**5.87%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IA** | Type of Reporting Person (See Instructions)<br>**IA** | |

---

| **CUSIP No.** | **04635X102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Magnetar Capital Partners LP** | Name of reporting person<br>**Magnetar Capital Partners LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3312202.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3312202.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.87%** | Percent of class represented by amount in Row (11)<br>**5.87%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

| **CUSIP No.** | **04635X102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Supernova Management LLC** | Name of reporting person<br>**Supernova Management LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3312202.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3312202.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.87%** | Percent of class represented by amount in Row (11)<br>**5.87%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**HC** | Type of Reporting Person (See Instructions)<br>**HC** | |

---

| **CUSIP No.** | **04635X102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**David J. Snyderman** | Name of reporting person<br>**David J. Snyderman** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**3312202.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**3312202.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | Aggregate amount beneficially owned by each reporting person<br>**3312202.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**5.87%** | Percent of class represented by amount in Row (11)<br>**5.87%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Astria Therapeutics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
22 Boston Wharf Road, 10th Floor, Boston, MA, 02210

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the 3,312,202 Shares reported herein on behalf of the Funds after the public announcement of the Agreement and Plan of Merger (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Company reported in their Form 8-K Report filed October 14, 2025, that 56,434,894 shares were outstanding as of October 10, 2025.

As of the close of business October 22, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 3,312,202 Shares, which consisted of (i) 1,507,698 Shares held for the benefit of PRA Master Fund, (ii) 776,947 Shares held for the benefit of Systematic Master Fund, (iii) 211,374 Shares held for the benefit of Relative Value Master Fund, and (iv) 816,183 Shares held for the benefit of the Managed Accounts, and all such Shares represented beneficial ownership of approximately 5.87% of the Shares.

**(b)**
As of the close of business October 22, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 3,312,202 Shares, which consisted of (i) 1,507,698 Shares held for the benefit of PRA Master Fund, (ii) 776,947 Shares held for the benefit of Systematic Master Fund, (iii) 211,374 Shares held for the benefit of Relative Value Master Fund, and (iv) 816,183 Shares held for the benefit of the Managed Accounts, and all such Shares represented beneficial ownership of approximately 5.87% of the Shares.

**(c)**
Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NASDAQ and various other trading markets.

As disclosed by the Company in the Form 8K filed with the SEC on October 14, 2025:

Agreement and Plan of Merger

On October 14, 2025, Astria Therapeutics, Inc., a Delaware corporation ("Astria"), BioCryst Pharmaceuticals, Inc., a Delaware corporation ("BioCryst"), and Axel Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BioCryst ("Merger Sub"), entered into an Agreement and Plan of Merger (the "Merger Agreement"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, at the Effective Time (as defined below), Merger Sub will merge with and into Astria, with Astria surviving the Merger as a wholly owned subsidiary of BioCryst (the "Merger").

Merger Consideration

Subject to the terms and conditions of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.001 per share, of Astria ("Astria Common Stock") issued and outstanding immediately prior to the Effective Time (subject to certain exceptions, including shares of Astria Common Stock owned by stockholders of Astria who have not voted in favor of the adoption of the Merger Agreement and have properly exercised appraisal rights in accordance with Section 262 of the General Corporation Law of the State of Delaware) will be converted into the right to receive (i) 0.59 (the "Exchange Ratio") of a share of common stock, par value $0.01 per share, of BioCryst ("BioCryst Common Stock") and, if applicable, cash in lieu of fractional shares, and (ii) $8.55 in cash, without interest (the "Per Share Cash Amount"), subject to adjustment as described below and subject to applicable withholding taxes (the consideration described in the foregoing clauses (i) and (ii), collectively, the "Merger Consideration").

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Magnetar Financial LLC

**Signature:** /s/ Hayley Stein

**Name/Title:** Hayley Stein, Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Mgmt LLC, GP of Magnetar Capital Partners LP, its Sol Mem

**Date:** 10/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Magnetar Capital Partners LP

**Signature:** /s/ Hayley Stein

**Name/Title:** Hayley Stein, Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC, its General Partner

**Date:** 10/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Supernova Management LLC

**Signature:** /s/ Hayley Stein

**Name/Title:** Hayley Stein, Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC

**Date:** 10/24/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** David J. Snyderman

**Signature:** /s/ Hayley Stein

**Name/Title:** Hayley Stein, Attorney-in-fact for David J. Snyderman

**Date:** 10/24/2025